Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy (MSK10-134)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Galinpepimut S (Primary) ; Montanide ISA-51; Sargramostim
- Indications Mesothelioma
- Focus Therapeutic Use
- Acronyms MSK10-134
- 31 Aug 2018 Biomarkers information updated
- 09 Mar 2018 Planned End Date changed from 1 Apr 2019 to 1 Apr 2021.
- 09 Mar 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.